Free Trial

Panbela Therapeutics (PBLA) Insider Trading & Ownership

Panbela Therapeutics logo
$0.36 +0.04 (+12.59%)
(As of 11/21/2024 ET)

Panbela Therapeutics (NASDAQ:PBLA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
0.01%
Number Of
Insiders Buying
(Last 3 Years)
0
Number Of
Insiders Selling
(Last 3 Years)
1
Amount Of
Insider Selling
(Last 3 Years)
$51,730.60
Get PBLA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Panbela Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

PBLA Insider Buying and Selling by Quarter

Panbela Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2023Goldman Sachs Group IncMajor ShareholderSell3,643$14.20$51,730.60  
(Data available from 1/1/2013 forward)

PBLA Insider Trading Activity - Frequently Asked Questions

The list of insiders at Panbela Therapeutics includes Goldman Sachs Group Inc. Learn more on insiders at PBLA.

0.01% of Panbela Therapeutics stock is owned by insiders. Learn more on PBLA's insider holdings.

The following insider sold PBLA shares in the last 24 months: Goldman Sachs Group Inc ($51,730.60).

Insiders have sold a total of 3,643 Panbela Therapeutics shares in the last 24 months for a total of $51,730.60 sold.

Panbela Therapeutics Key Executives

  • Dr. Jennifer K. Simpson CRNP (Age 56)
    M.S.N., Ph.D., CEO, President & Director
    Compensation: $527k
  • Ms. Susan Horvath (Age 65)
    VP of Finance, CFO, Secretary & Treasurer
    Compensation: $452.39k
  • Ms. Tammy Groene
    Vice President of Operations


This page (NASDAQ:PBLA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners